Novimmune

Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases.[1] The company was founded in 1998.[2]

Novimmune has six publicly disclosed drug in their pipeline:

No drugs have been approved yet.

References

[edit]
  1. ^ "Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH) - FierceBiotech". www.fiercebiotech.com.
  2. ^ "Novimmune SA: Private Company Information - Bloomberg". www.bloomberg.com.
  3. ^ "First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers - Full Text View - ClinicalTrials.gov".
  4. ^ "Pipeline - NI-0101 anti-TLR4". www.novimmune.com.
  5. ^ "NI-0401 in Patients With Acute Renal Allograft Rejection - Full Text View - ClinicalTrials.gov".
  6. ^ "Pipeline | NI-0501 anti-IFNγ". Archived from the original on 2017-01-13. Retrieved 2017-01-11.
  7. ^ "Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody - Full Text View - ClinicalTrials.gov".
  8. ^ "A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis - Full Text View - ClinicalTrials.gov".
  9. ^ "Emapalumab - NovImmune - AdisInsight". adisinsight.springer.com.
  10. ^ "Pipeline - NI-1401 anti-IL17". www.novimmune.com.
  11. ^ "Pipeline - NI-1801 anti-CD47/Mesothelin". www.novimmune.com.